Repros in the News

All Releases

View Summary Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results

Nov 13, 2017

PDF 24.5 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results

Aug 14, 2017

PDF 27.6 KB Add to Briefcase
View Summary Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA

Jul 17, 2017

PDF 20.3 KB Add to Briefcase
View Summary Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock

May 18, 2017

PDF 18.5 KB Add to Briefcase
View Summary Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

May 17, 2017

PDF 16.7 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results

May 9, 2017

PDF 24.1 KB Add to Briefcase
View Summary Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions

Apr 17, 2017

PDF 15.8 KB Add to Briefcase
View Summary Repros Names Larry Dillaha, M.D., its Permanent President and CEO

Apr 10, 2017

PDF 16.2 KB Add to Briefcase
View Summary Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids

Apr 10, 2017

PDF 16.4 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results

Mar 31, 2017

PDF 24.9 KB Add to Briefcase
View Summary Repros Announces New CEO

Feb 2, 2017

PDF 16.3 KB Add to Briefcase
View Summary FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids

Jan 30, 2017

PDF 16.5 KB Add to Briefcase
View Summary Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis

Dec 19, 2016

PDF 16.2 KB Add to Briefcase
View Summary Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids

Dec 12, 2016

PDF 19.1 KB Add to Briefcase
View Summary FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

Dec 6, 2016

PDF 16.6 KB Add to Briefcase
View Summary Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids

Nov 14, 2016

PDF 20.4 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results

Nov 8, 2016

PDF 24.5 KB Add to Briefcase
View Summary Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities

Oct 5, 2016

PDF 18.9 KB Add to Briefcase
View Summary FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

Sep 26, 2016

PDF 18.6 KB Add to Briefcase
View Summary Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism

Sep 12, 2016

PDF 19.6 KB Add to Briefcase
Showing 1-20 of 196 Page: 1 2 3 4 5 ... 10  Next 20
Add to Briefcase = add release to Briefcase
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax